CURLF Curaleaf Holdings, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1756770 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.9%
TTM net income YoY23.4%
TTM EPS YoY17.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR—
Margins
Gross margin48.0%
Operating margin1.9%
Net margin-16.1%
FCF margin5.3%
EBITDA margin19.2%
Returns
ROE-22.5%
ROA-7.1%
ROIC (approx.)1.4%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets66.3%
Debt / equity0.66x
Current ratio1.12x
Interest coverage0.47x
Cash quality & payout
Operating cash flow / net income-0.76x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.27B | $1.33B |
| Cost of revenue | $637.11M | $693.52M |
| Gross profit | $631.02M | $640.78M |
| R&D expense | $805,000 | $1.42M |
| SG&A expense | $428.44M | $418.53M |
| Operating income | $25.45M | $24.74M |
| Interest expense | $53.52M | $53.19M |
| Pretax income | -$78.21M | -$113.36M |
| Income tax | $123.69M | $98.25M |
| Net income | -$231.07M | -$215.42M |
| EBITDA | $222.06M | $256.20M |
| EPS (basic) | -0.35 | -0.32 |
| EPS (diluted) | -0.35 | -0.32 |
| Weighted avg. shares (diluted) | 762.09M | 740.83M |
| Balance sheet | ||
| Cash & equivalents | $89.21M | $107.22M |
| Receivables | $73.86M | $63.99M |
| Inventory | $225.02M | $216.94M |
| Current assets | $448.62M | $434.37M |
| PP&E, net | $520.39M | $542.60M |
| Goodwill | $635.12M | $628.88M |
| Intangibles | $1.01B | $1.09B |
| Total assets | $2.85B | $2.95B |
| Current liabilities | $294.31M | $387.93M |
| Short-term debt | $35.73M | $101.72M |
| Long-term debt | $512.92M | $466.90M |
| Total debt | $548.65M | $568.62M |
| Total liabilities | $2.01B | $1.96B |
| Shareholders' equity | $756.35M | $861.21M |
| Net debt | $459.44M | $461.39M |
| Shares outstanding | 257.49M | 750.06M |
| Cash flow statement | ||
| Operating cash flow | $137.71M | $163.62M |
| Capital expenditure | $63.44M | $92.44M |
| Free cash flow | $74.27M | $71.19M |
| Investing cash flow | -$70.34M | -$93.83M |
| Financing cash flow | -$73.49M | -$54.24M |
| Depreciation & amortization | $196.61M | $231.46M |
| Stock-based compensation | $35.74M | $25.70M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.